A study evaluating the safety, tolerability, pharmacokinetics, and activity of RO7566802 given alone and in combination with atezolizumab in patients with locally advanced or metastatic solid tumor malignancies

Status Authorised, recruitment pending · 2 EU/EEA countries · 7 sites · Protocol GO44431

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans

Status Authorised, recruitment pending

Participants planned 134

Countries 2

Sites 7

Locally Advanced or Metastatic Solid Tumors

Key facts

Sponsor: Genentech Inc.
Participant type: Patients
Age range: 18-64 years, 65+ years
Gender: Male and Female
Therapeutic area: Diseases [C] - Neoplasms [C04]
Decision date (initial): 2025-02-24
Transition trial: No
Low-intervention: No
Rare-disease indication: No
Vulnerable population: No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Locally Advanced or Metastatic Solid Tumors

Version	Level	Code	Term	System organ class
20.0	PT	10033128	Ovarian cancer	100000004864
27.0	PT	10057529	Ovarian cancer metastatic	100000004864
21.0	PT	10073251	Clear cell renal cell carcinoma	100000004864
20.1	LLT	10080007	Clear cell renal cell carcinoma metastatic	10029104
21.1	LLT	10065252	Solid tumor	10029104
21.1	LLT	10065147	Malignant solid tumor	10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Genentech Inc.

Sponsor organisation: Genentech Inc.
Address: 1 Dna Way
City: South San Francisco
Postcode: 94080-4918
Country: United States

Scientific contact point

Organisation: Genentech Inc.
Contact name: US Program Manager Product Development Regulatory

Public contact point

Organisation: Genentech Inc.
Contact name: US Program Manager Product Development Regulatory

Locations

2 EU/EEA countries · 7 investigational sites

By country

Country	MS status	Planned subjects	Sites
Czechia	Authorised, recruitment pending	8	2
Spain	Authorised, recruitment pending	15	5
Rest of world Singapore, United States, United Kingdom, Australia, Korea, Republic of, Canada	—	111	—

Investigational sites

Czechia

2 sites · Authorised, recruitment pending

University Hospital Olomouc

n/a, Zdravotniku 248/7, 779 00, Olomouc

Masarykuv Onkologicky Ustav

n/a, Zluty Kopec 543/7, Stare Brno, Brno-Stred

Spain

5 sites · Authorised, recruitment pending

Clinica Universidad De Navarra

Servicio de oncologia, Pio XII Etorbidea 36, 31008, Pamplona

Hospital Universitario Fundacion Jimenez Diaz

Servicio de oncologia, Avenida De Los Reyes Catolicos 2, 28040, Madrid

Hospital Clinico Universitario De Valencia

Servicio de oncologia, Avenida Blasco Ibanez 17, 46010, Valencia

Hospital Universitari Vall D Hebron

Servicio de oncologia, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona